Achieving ultimate control of hepatitis B infection in China
Epidemiology and prevention of hepatitis B virus infection in China
Management of chronic hepatitis B
Serum peptide profiles during progression of chronic hepatitis B virus infection to liver failure
Telbivudine preserves T-helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis
Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses
Significant histopathology in Chinese chronic hepatitis B patients with persistently high–normal alanine aminotransferase
Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients
Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients
rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B